Figure 2.Recommendations for the treatment of previously treated patients with Waldenstrom’s Macroglobulinemia. Figure adjusted from ESMO guidelines for WM 2018 and EMN recommendations for treatment of rare plasma cell dyscrasias. R: rituximab.
Figure 2 — How I treat elderly patients with plasma cell dyscrasias | Aging
